Drug Profile
Nanoflavopiridol - JYANT Technologies
Alternative Names: nanoalvocidib - JYANT TechnologiesLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator JYANT Technologies
- Class Antineoplastics; Benzopyrans; Chlorinated hydrocarbons; Flavonoids; Ketones; Piperidines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; CDC2 protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Prostate-cancer(Hormone refractory) in USA
- 12 Aug 2016 Early research in Prostate cancer (Hormone refractory) in USA (unspecified route)